UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

FORM 8-K

CURRENT REPORT
Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934

Date of Report (date of earliest event reported): December 11, 2023

TARSUS PHARMACEUTICALS, INC.

(Exact name of registrant as specified in its charter)

Delaware	**001-39614**	**81-4717861**
(State or other jurisdiction of incorporation)	**(Commission File Number)**	**(I.R.S. Employer Identification No.)**

15440 Laguna Canyon Road, Suite 160
Irvine, CA 92618
(Address of principal executive offices, including Zip Code)

Registrant's telephone number, including area code: (949) 409-9820

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class	Trading Symbol(s)	Name of each exchange on which registered
Common Stock, $0.0001 par value per share	TARS	The Nasdaq Stock Market LLC Nasdaq Global Select Market

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter). Emerging growth company ☒

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☒

Item 8.01 Other Events.

On December 11, 2023, Tarsus Pharmaceuticals, Inc. (the "Company") announced positive topline results of the Company's Ersa Phase 2a clinical trial evaluating TP-03 (lotilaner ophthalmic solution, 0.25%) administered twice daily (BID) or three times a day (TID) for 12 weeks for the treatment of Meibomian Gland Disease (MGD) in patients with *Demodex* mites. A corporate presentation which includes a summary of the topline clinical results of the Ersa trial is filed as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated herein by reference.

Item 9.01 Financial Statements and Exhibits.

(d) Exhibits.

Exhibit No.	Description
99.1	Tarsus Pharmaceuticals, Inc. Corporate Presentation.
104	Cover Page Interactive Data File (embedded within XBRL document)

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

TARSUS PHARMACEUTICALS, INC.

Date: December 11, 2023

/s/ Jeffrey S. Farrow

Jeffrey S. Farrow
Chief Financial Officer and Chief Strategy Officer
(Principal Financial Officer and Principal Accounting Officer)

Ersa Phase 2a Study Evaluati
TP-03 for the Treatment of MC
in Patients with *Demodex* Mit
Topline Data Presentati

December

tarsus

Legal Disclaimer

This presentation contains forward-looking statements that involve risks and uncertainties. Forward-looking statements are neither historical facts nor assurances of future performance. Instead, they are based on our current expectations about future events that we believe may affect our financial condi results of operations, business strategy, and financial needs. All statements other than statements of historical facts contained in this presentation, includ any statements regarding the timing, objectives, and results of the clinical trials including the complete clinical results of the Ersa trial and anticipated reg and development milestones are forward-looking statements. The words “may,” “will,” “expect,” “anticipate,” “aim,” “estimate,” “intend,” “plan,” “believe,” likely to,” “potential,” “continue” and other similar expressions are intended to identify forward-looking statements, although not all forward-looking statem contain these identifying words. Forward-looking statements may involve known and unknown risks, uncertainties and other factors that may cause our a results, performance or achievements to be materially different from those expressed or implied by the forward-looking statements. Accordingly, readers cautioned not to place undue reliance on these forward-looking statements. Except as required by applicable law, we do not plan to publicly update or re any forward-looking statements contained herein, whether as a result of any new information, future events, changed circumstances or otherwise. No representations or warranties (expressed or implied) are made about the accuracy of any such forward-looking statements. Important factors that could c our actual results to differ materially are detailed from time to time in the reports we file with the Securities and Exchange Commission, copies of which a posted on our website and are available from us without charge. However, new risk factors and uncertainties may emerge from time to time, and it is not possible to predict all risk factors and uncertainties.

Ersa Phase 2a Study Evaluating TP-03 for the Treatment of Meibomian Gland Disease in Patients with *Demodex* Mites

- **TP-03 (lotilaner ophthalmic solution 0.25%) demonstrated statistically significant improvements compared to baseline in objective measures of meibomian gland function at 6 and 12 weeks**
  - Meibomian gland secretion score (MGSS) at Day 43 (6 weeks) and Day 85 (12 weeks) demonstrated a statistically significant clinically meaningful improvement over baseline
  - Number of glands secreting clear meibum demonstrated statistically significant and clinically meaningful improvement from baseline to Day 43 and 85
  - There were no significant differences between BID and TID across all measures
- **Collarette cure and lid margin erythema cure demonstrated statistically significant improvement consistent with prior TP-03 studies**
- **TP-03 was generally well-tolerated**
- **FDA discussion planned for 2024**

Ersa Phase 2a Study Overview

- Randomized, Double-Masked, Pilot Study Comparing the Safety and Efficacy of Two Dosing Regimens (BID vs TID) of TP-03 for the Treatment of MGD in Patients with *Demodex* mites
- 39 patients randomized to BID/TID arms
- Endpoints collected included safety assessments, meibomian gland function, DB endpoints and patient-reported symptoms



TP-03 Treatment Significantly Improves Meibomian Gland Function

- Demonstrated a significant and clinically meaningful increase from baseline that was observed in the mean MGSS c 10.5 (± 1.6 standard error, SE) and 11.7 (± 1.9 SE) for the BID and TID arms, respectively, at Day 85 ($p < 0.001$)
- No statistically significant differences between BID and TID treatment groups



*MGSS Score Range 0-45

TP-03 Treatment Significantly Improves Meibomian Gland Secretion

- Demonstrated improvement in the mean number of meibomian glands secreting clear liquid from baseline that was statistically significant and clinically meaningful, with an increase of 4.8 (± 0.8 SE) and 5.3 (± 1.1 SE) glands for the and TID arms, respectively, at Day 85 ($p < 0.001$)
- No statistically significant differences between BID and TID treatment groups



Ersa MGD Phase 2a Study Safety and Tolerability

- **TP-03 was generally well tolerated following 12 week of treatment period**
  - Most Adverse Events (AEs) were mild
    - 2 Drug-related AEs were mild (5.1%): 1 case of ocular discomfort in the BID arm and 1 case of conjunctivitis in the TID ar
- **No related Serious Adverse Events (SAEs)**
  - 1 unrelated SAE of presyncope
- **No treatment-related discontinuations**